93 related articles for article (PubMed ID: 21489757)
1. Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.
Weng TC; Chen YH; Lee CC; Wang CY; Lai CC; Tang HJ; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2011 Jun; 37(6):581-4. PubMed ID: 21489757
[No Abstract] [Full Text] [Related]
2. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
3. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
Ray GT; Baxter R; DeLorenze GN
Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150
[TBL] [Abstract][Full Text] [Related]
4. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France.
Miliani K; L'Hériteau F; Lacavé L; Carbonne A; Astagneau P;
J Hosp Infect; 2011 Apr; 77(4):343-7. PubMed ID: 21316805
[TBL] [Abstract][Full Text] [Related]
5. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
Prasad SV; Ballal M; Shivananda PG
Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
[TBL] [Abstract][Full Text] [Related]
6. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital.
Erdeljić V; Francetić I; Bošnjak Z; Budimir A; Kalenić S; Bielen L; Makar-Aušperger K; Likić R
Int J Antimicrob Agents; 2011 May; 37(5):467-71. PubMed ID: 21277747
[TBL] [Abstract][Full Text] [Related]
7. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study.
Lafaurie M; Porcher R; Donay JL; Touratier S; Molina JM
J Antimicrob Chemother; 2012 Apr; 67(4):1010-5. PubMed ID: 22240401
[TBL] [Abstract][Full Text] [Related]
8. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.
Polk RE; Johnson CK; McClish D; Wenzel RP; Edmond MB
Clin Infect Dis; 2004 Aug; 39(4):497-503. PubMed ID: 15356812
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.
MacDougall C; Harpe SE; Powell JP; Johnson CK; Edmond MB; Polk RE
Emerg Infect Dis; 2005 Aug; 11(8):1197-204. PubMed ID: 16102307
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Guss J; Abuzeid WM; Doghramji L; Edelstein PH; Chiu AG
ORL J Otorhinolaryngol Relat Spec; 2009; 71(5):263-7. PubMed ID: 19797934
[TBL] [Abstract][Full Text] [Related]
11. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
Ogbolu DO; Ogunledun A; Adebiyi OE; Daini OA; Alli AO
Afr J Med Med Sci; 2008 Dec; 37(4):339-44. PubMed ID: 19301711
[TBL] [Abstract][Full Text] [Related]
13. Resistance rates of Pseudomonas aeruginosa and Acinetobacter species causing ventilator-associated pneumonia do not always correlate with utilisation of antibiotics.
Jankovic S; Djordjevic Z; Matovic M
J Hosp Infect; 2011 Jan; 77(1):77-8. PubMed ID: 21122946
[No Abstract] [Full Text] [Related]
14. Fluoroquinolone use and fluoroquinolone-resistant Pseudomonas aeruginosa is declining in US academic medical centre hospitals.
Pakyz AL; Lee JA; Ababneh MA; Harpe SE; Oinonen MJ; Polk RE
J Antimicrob Chemother; 2012 Jun; 67(6):1562-4. PubMed ID: 22416053
[No Abstract] [Full Text] [Related]
15. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan.
Hsueh PR; Tseng SP; Teng LJ; Ho SW
Clin Microbiol Infect; 2005 Aug; 11(8):670-3. PubMed ID: 16008621
[TBL] [Abstract][Full Text] [Related]
16. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.
Gallini A; Degris E; Desplas M; Bourrel R; Archambaud M; Montastruc JL; Lapeyre-Mestre M; Sommet A
J Antimicrob Chemother; 2010 Dec; 65(12):2650-7. PubMed ID: 20876240
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003).
Sánchez-Romero I; Cercenado E; Cuevas O; García-Escribano N; García-Martínez J; Bouza E;
Rev Esp Quimioter; 2007 Jun; 20(2):222-9. PubMed ID: 17893760
[TBL] [Abstract][Full Text] [Related]
18. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit.
Aubert G; Carricajo A; Vautrin AC; Guyomarc'h S; Fonsale N; Page D; Brunel P; Rusch P; Zéni F
J Hosp Infect; 2005 Feb; 59(2):83-9. PubMed ID: 15620440
[TBL] [Abstract][Full Text] [Related]
19. In vitro fluoroquinolone susceptibility of Pseudomonas aeruginosa isolates from dogs with ulcerative keratitis.
Ledbetter EC; Hendricks LM; Riis RC; Scarlett JM
Am J Vet Res; 2007 Jun; 68(6):638-42. PubMed ID: 17542697
[TBL] [Abstract][Full Text] [Related]
20. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
Jónsdóttir K; Kristinsson KG
Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
